Efficacy and safety of Siddha Vatha ennai in Benign Paroxysmal Positional Vertigo

A Randomized, double blind, Controlled Pilot Clinical Trial to evaluate the Safety and Efficacy of Siddha herbal oil Vatha Ennai vs Standard Care in patients diagnosed with Benign Paroxysmal Positional Vertigo - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/107435

Enrollment

Registered

2026-04-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H811- Benign paroxysmal vertigo

Interventions

Intervention1: Vatha ennai: Internal administration of Siddha Vatha ennai, 1-2ml orally twice daily for 48 days Control Intervention1: Standard of care: Epley/Gufoni maneuver and vestibular suppressa

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of Vertigo confirmed by Dix Hallpike or Roll test with at least a duration of 3 months Willingness to adhere to the 48 day Vatha ennai regimen.

Exclusion criteria

Exclusion criteria: Central vertigo or other vestibular disorders (e.g vestibular neuritis). Significant cardiovascular, hepatic, or renal pathology. Hypersensitivity to any ingredient of Vathaennai. Pregnant or lactating women. Concurrent use of other investigational drugs or traditional vertigo remedies. Severe psychiatric illness or cognitive impairment affecting protocol compliance.

Design outcomes

Primary

Measure	Time frame
Change in vertigo symptom severity from baseline to Day 48 measured by the Dizziness Handicap InventoryTimepoint: Baseline, fifteen, thirty, forty eight days	—

Secondary

Measure	Time frame
Change in quality of life & functional impact assessed using the Dizziness Handicap Inventory DHI Vertigo Symptom Scale VSS & EQ 5D 5L Proportion of participants with conversion from a positive Dix Hallpike or Roll test at baseline to a negative test at Day 15 Day 30 & Day 48 Safety & tolerability of Vatha Ennai assessed through systematic monitoring & reporting of adverse events Preliminary treatment effect size estimation for planning future comparative clinical trials Treatment adherence & feasibility assessed through patient compliance follow up retention & documentation of reasons for missed doses or study visitsTimepoint: Baseline, fifteen, thirty, forty eight days	—

Measure

Time frame

Change in quality of life & functional impact assessed using the Dizziness Handicap Inventory DHI Vertigo Symptom Scale VSS & EQ 5D 5L Proportion of participants with conversion from a positive Dix Hallpike or Roll test at baseline to a negative test at Day 15 Day 30 & Day 48 Safety & tolerability of Vatha Ennai assessed through systematic monitoring & reporting of adverse events Preliminary treatment effect size estimation for planning future comparative clinical trials Treatment adherence & feasibility assessed through patient compliance follow up retention & documentation of reasons for missed doses or study visitsTimepoint: Baseline, fifteen, thirty, forty eight days

—

Countries

India

Contacts

Public ContactDr G J Christian

National Institute of Siddha

spaargavi@gmail.com9789452792

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026